Recruiting
Clinical Trial 18-443: Patients with Burkitt’s Lymphoma/Leukemia or High-Grade B-cell Lymphoma
To determine the overall response rate of CPI-613® in patients with relapsed or refractory Burkitt’s Lymphoma/Leukemia and double hit/ diffuse large B cell lymphoma analyzed as two separate cohorts.